As Ontario, Nova Scotia and other provinces distribute second doses of the AstraZeneca vaccine to residents, there is good news about the troubled COVID-19 vaccine. Not only are doctors and researchers around the world getting faster at recognizing, diagnosing and treating the rare blood clotting syndrome that can occur after a shot of the vaccine, but there is now hope that scientists are zeroing in on what causes vaccine-induced immune thrombotic thrombocytopenia (VITT). The syndrome, which can occur between four and 28 days after vaccination, features both blood clots and low platelet counts. And it’s those tiny blood cells, which work by forming blood clots to stop bleeding, that are key to identifying VITT in patients.
Researchers at Goethe University in Germany think they may have found a solution to the VITT problem. They believe the issue is with how the vaccine delivers the spike protein of the SARS-CoV-2 virus into the body. In rare cases, it doesn’t bind to the cell membrane but is released into the bloodstream where it interacts with antibodies and causes clotting events. If proved right, the Goethe scientists believe the vaccine could be tweaked to avoid that occurrence, and thus stop VITT.
In Canada, VITT is diagnosed at the McMaster Platelet Immunology Laboratory (MPIL) in Hamilton, Ont.. It’s the only lab in the nation capable of confirming VITT. Physicians send clinical information about patients who might have the syndrome to the laboratory and then ship blood samples, explains Dr. Ishac Nazy, the lab’s director and an associate professor at McMaster University. It’s a two step-process. First the lab does a screening test, looking for a specific type of antibody. That test takes a few hours of lab work. If it’s negative, the patient doesn’t have VITT.
If it’s positive, lab personnel run a functional platelet-activating test. The test was originally developed at the McMaster lab to look for heparin-induced thrombocytopenia (HIT), which activates platelets that can form blood clots. Scientists realized that VITT acts in a similar fashion (but doesn’t require heparin as a trigger). If the patient has activated platelets, then they have VITT. MPIL then informs the doctors, so they can continue treating the person for the syndrome.
VITT is very rare. In Canada, it occurs in roughly one in every 58,000 people who got a first dose of AstraZeneca, though that ratio is below one in 20,000 in Scandinavia. For second doses, the ratio is roughly one in 600,000, according to data in Britain, where tens of millions of AstraZeneca doses have been administered.
“For every case that we identify, we are testing tens and hundreds of samples. We want to make sure we don’t miss any,” Nazy says. “So we advise the doctors that if you suspect it and have the slightest evidence it is VITT, send it our way.”
Looking for more?
Get the best of ishonest straight to your inbox. Sign up for your daily dose of news, commentary and analysis.
Read more on: news
Learn about unknown needs of your skin for free